On the client side, there were three pharma companies at the top of the leader board. Novartis (including Novartis and ...

The new head of Novartis UK thinks the country has gone backwards in terms of access to medicines, and says his company is moving towards 'payments for outcomes'. Haseeb Ahmad is the new managing ...

The decision also creates a disparity in access within the UK as Aimovig was backed in April for NHS use in Scotland by the SMC, NICE’s north-of-the-border equivalent. Novartis said in a ...

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population. The ...

NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering ...

MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.

Investing.com -- Shares of Novartis (LON:0QLR) (SIX:NOVN) were down on Wednesday following a downgrade by BofA Securities, which downgraded the Swiss pharmaceutical giant to "neutral" from "buy." At 4 ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Country President Novartis UK and Ireland. “In securing access for eligible patients to the first oral monotherapy to become available in PNH, we are again demonstrating our commitment to UK life ...

On Friday, BMO Capital maintained its Market Perform rating and $118.00 stock price target on Novartis (LON:0QLR) (SIX:NOVN) (NYSE:NVS), following discussions with the company's CFO Harry Kirsch. The ...

Metformin does not improve survival in unselected patients with metastatic hormone-sensitive prostate cancer (mHSPC), but the drug may improve survival and other outcomes in those with high-volume ...